LIVIVO - Search results -

Search results

Result 1 - 10 of total 69

Book: Lupus erythematosus

Schur, Peter H. / Massarotti, Elena M.

clinical evaluation and treatment

2012

Author's details	Peter H. Schur ; Elena M. Massarotti ed
Keywords	Systemic lupus erythematosus ; Systemic lupus erythematosus--Diagnosis ; Systemic lupus erythematosus--Treatment
Language	English
Size	XI, 260 S. : Ill., graph. Darst., 24 cm
Publisher	Springer
Publishing place	New York u.a.
Publishing country	United States
Document type	Book
HBZ-ID	HT017356035
ISBN	978-1-4614-1188-8 ; 1-4614-1188-2 ; 9781461411895 ; 1461411890
Database	Catalogue ZB MED Medicine, Health

In stock of ZB MED Cologne/Königswinter

Shelf mark	Loan status	Location
2012 A 3379	order for loan	Magazin

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Improvement in joint inflammation is accompanied by reduction in arterial inflammation: Tocilizumab in rheumatoid arthritis.

Zureigat, Hadil / Civieri, Giovanni / Abohashem, Shady / Osborne, Michael T / Solomon, Daniel H / Giles, Jon T / Bathon, Joan / Massarotti, Elena / Unizony, Sebastian / Tawakol, Ahmed

Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology

2024 Volume 33, Page(s) 101813

MeSH term(s)	Humans ; Arthritis, Rheumatoid/diagnostic imaging ; Arthritis, Rheumatoid/drug therapy ; Antibodies, Monoclonal, Humanized/therapeutic use ; Inflammation ; Arteritis ; Treatment Outcome
Chemical Substances	tocilizumab (I031V2H011) ; Antibodies, Monoclonal, Humanized
Language	English
Publishing date	2024-01-22
Publishing country	United States
Document type	Journal Article
ZDB-ID	1212505-2
ISSN	1532-6551 ; 1071-3581
ISSN (online)	1532-6551
ISSN	1071-3581
DOI	10.1016/j.nuclcard.2024.101813
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 4121: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Reasons for multiple biologic and targeted synthetic DMARD switching and characteristics of treatment refractory rheumatoid arthritis.

McDermott, Gregory C / DiIorio, Michael / Kawano, Yumeko / Jeffway, Mary / MacVicar, Megan / Dahal, Kumar / Moon, Su-Jin / Seyok, Thany / Coblyn, Jonathan / Massarotti, Elena / Weinblatt, Michael E / Weisenfeld, Dana / Liao, Katherine P

Seminars in arthritis and rheumatism

2024 Volume 66, Page(s) 152421

Abstract: Objective: Switching biologic and targeted synthetic DMARD (b/tsDMARD) medications occurs commonly in RA patients, however data are limited on the reasons for these changes. The objective of the study was to identify and categorize reasons for b/tsDMARD ...

Abstract	Objective: Switching biologic and targeted synthetic DMARD (b/tsDMARD) medications occurs commonly in RA patients, however data are limited on the reasons for these changes. The objective of the study was to identify and categorize reasons for b/tsDMARD switching and investigate characteristics associated with treatment refractory RA. Methods: In a multi-hospital RA electronic health record (EHR) cohort, we identified RA patients prescribed ≥1 b/tsDMARD between 2001 and 2017. Consistent with the EULAR "difficult to treat" (D2T) RA definition, we further identified patients who discontinued ≥2 b/tsDMARDs with different mechanisms of action. We performed manual chart review to determine reasons for medication discontinuation. We defined "treatment refractory" RA as not achieving low disease activity (<3 tender or swollen joints on <7.5 mg of daily prednisone equivalent) despite treatment with two different b/tsDMARD mechanisms of action. We compared demographic, lifestyle, and clinical factors between treatment refractory RA and b/tsDMARD initiators not meeting D2T criteria. Results: We identified 6040 RA patients prescribed ≥1 b/tsDMARD including 404 meeting D2T criteria. The most common reasons for medication discontinuation were inadequate response (43.3 %), loss of efficacy (25.8 %), and non-allergic adverse events (13.7 %). Of patients with D2T RA, 15 % had treatment refractory RA. Treatment refractory RA patients were younger at b/tsDMARD initiation (mean 47.2 vs. 55.2 years, p < 0.001), more commonly female (91.8% vs. 76.1 %, p = 0.006), and ever smokers (68.9% vs. 49.9 %, p = 0.005). No RA clinical factors differentiated treatment refractory RA patients from b/tsDMARD initiators. Conclusions: In a large EHR-based RA cohort, the most common reasons for b/tsDMARD switching were inadequate response, loss of efficacy, and nonallergic adverse events (e.g. infections, leukopenia, psoriasis). Clinical RA factors were insufficient for differentiating b/tsDMARD responders from nonresponders.
Language	English
Publishing date	2024-03-01
Publishing country	United States
Document type	Journal Article
ZDB-ID	120247-9
ISSN	1532-866X ; 0049-0172
ISSN (online)	1532-866X
ISSN	0049-0172
DOI	10.1016/j.semarthrit.2024.152421
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 790: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Safety of the Zoster Vaccine Recombinant Adjuvanted in Rheumatoid Arthritis and Other Systemic Rheumatic Disease Patients: A Single Center's Experience With 400 Patients.

Stevens, Emma / Weinblatt, Michael E / Massarotti, Elena / Griffin, Frances / Emani, Srinivas / Desai, Sonali

ACR open rheumatology

2020 Volume 2, Issue 6, Page(s) 357–361

Abstract: Objective: Patients with rheumatoid arthritis (RA) and other systemic rheumatic diseases (SRDs) are at increased risk of developing herpes zoster (HZ). Zoster recombinant adjuvanted (ZRA) is a recombinant vaccine approved by the Food and Drug ... ...

Abstract	Objective: Patients with rheumatoid arthritis (RA) and other systemic rheumatic diseases (SRDs) are at increased risk of developing herpes zoster (HZ). Zoster recombinant adjuvanted (ZRA) is a recombinant vaccine approved by the Food and Drug Administration in 2018. Concern has been raised that the ZRA may trigger disease flares in rheumatology patients who are immunocompromised. We investigated the impact of the ZRA vaccine in patients with RA and SRD and measured the incidence of flares and side effects. Methods: A flare was defined as occurring within 12 weeks of vaccine administration by either 1) documentation of RA flare in office notes, telephone encounter, or patient portal communication or 2) new or increased dose of corticosteroids. Results: We identified 403 patients (239 patients with RA and 164 patients with SRD) who received the ZRA vaccine from February 1, 2018, to February 1, 2019. We measured a 6.7% (n = 27) incidence of flare. Side effects occurred in 12.7% (n = 51) of patients. All flares and side effects were regarded as mild. Three cases of HZ were reported as occurring 2, 10, and 11 months after the vaccination. Conclusion: In 403 patients who received the ZRA vaccine, the incidence of disease flares was 7% or less and that of side effects was 13% or less, both of which are less than the incidence rates observed in the pivotal trials.
Language	English
Publishing date	2020-05-15
Publishing country	United States
Document type	Journal Article
ISSN	2578-5745
ISSN (online)	2578-5745
DOI	10.1002/acr2.11150
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Inter-library loan at ZB MED

Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

Article: Clinical and patient-reported outcomes in clinical trials of abatacept in the treatment of rheumatoid arthritis.

Massarotti, Elena M

Clinical therapeutics

2008 Volume 30, Issue 3, Page(s) 429–442

Abstract: Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, which if left untreated leads to progressive disability and joint destruction. A combination of antiinflammatory agents, steroids, disease- ... ...

Abstract	Background: Rheumatoid arthritis (RA) is an autoimmune disease characterized by chronic joint inflammation, which if left untreated leads to progressive disability and joint destruction. A combination of antiinflammatory agents, steroids, disease-modifying antirheumatic drugs, and biological agents are used to treat RA. Beyond the use of conventional measures of disease activity, such as American College of Rheumatology (ACR) response rates, the importance of patient-reported outcomes (PROs) in assessing therapeutic benefits is gaining increasing emphasis in clinical trials of RA and other chronic illnesses. Clinical trials testing new RA therapeutics generally include health-related quality of life (HRQoL) measures and assessments of function and disability. Abatacept, a costimulation modulator that selectively targets the activation of T cells and downregulates the immune response, has been approved by the US Food and Drug Administration for the treatment of RA, with or without methotrexate. Objective: The aim of this review was to summarize the clinical outcomes and PROs in published trials of abatacept. Methods: A literature search was performed using the MEDLINE, EMBASE, and BIOSIS databases (restricted to articles posted between January 2000 and September 2007) with the search terms CTLA-4Ig, abatacept, and Orencia to identify published trials of abatacept. Primary clinical trial publications in patients with RA were selected. The ACR response and PROs data presented in the identified publications are summarized in this review. Results: Our search identified 6 studies that met our selection criteria, which included 1 Phase IIa study, 2 Phase IIb studies, and 3 Phase III studies. The Phase IIa study found that abatacept was more effective than placebo and that physical function improved in treated patients compared with placebo. The 2 Phase IIb studies in 339 patients with RA previously treated with methotrexate found statistically significant improvements in HRQoL with abatacept at 6 months and 1 year. Similar findings were noted in the published Phase III trials. Across clinical trials, abatacept has been associated with clinically meaningful and statistically significant improvements in conventional measures of disease activity, HRQoL, and physical function. Conclusions: These 6 published trials found that abatacept was associated with significant improvements in both conventional measures of disease activity and PROs. Continued assessment of these outcomes will be required to further support the findings of the Phase II and III abatacept clinical trial literature reviewed here.
MeSH term(s)	Abatacept ; Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/drug therapy ; Clinical Trials as Topic/statistics & numerical data ; Health Status ; Humans ; Immunoconjugates/therapeutic use ; Pilot Projects ; Quality of Life ; Treatment Outcome
Chemical Substances	Antirheumatic Agents ; Immunoconjugates ; Abatacept (7D0YB67S97)
Language	English
Publishing date	2008-03
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	603113-4
ISSN	1879-114X ; 0149-2918
ISSN (online)	1879-114X
ISSN	0149-2918
DOI	10.1016/j.clinthera.2008.03.002
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1435: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 404: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: The potential role of ‘non-rheumatic’ therapies in rheumatic disease.

Massarotti, Elena M / Solomon, Daniel H

Arthritis research & therapy

2013 Volume 15, Issue 6, Page(s) 124

Abstract: The relationship between inflammation and insulin resistance is complex and not fully understood. Patients with rheumatoid arthritis are at increased risk of mortality from cardiovascular disease, which is known to be associated with insulin resistance. ... ...

Abstract	The relationship between inflammation and insulin resistance is complex and not fully understood. Patients with rheumatoid arthritis are at increased risk of mortality from cardiovascular disease, which is known to be associated with insulin resistance. In the previous issue of Arthritis Research & Therapy, Ormseth and colleagues report the results of an 8-week trial of pioglitazone, an agent commonly used to treat type 2 diabetes mellitus, upon the DAS-28 (disease activity score using 28 joint counts). Modest improvements in the DAS-28 CRP (DAS-28 C-reactive protein) were shown, with no effect on DAS-28 ESR (DAS-28 erythrocyte sedimentation rate). Other variables that improved with pioglitazone were the CRP, IL-6, and patient-reported assessment of global health. The authors discuss the contribution of insulin resistance to the inflammation noted in rheumatoid arthritis.
MeSH term(s)	Arthritis, Rheumatoid/drug therapy ; Female ; Humans ; Male ; PPAR gamma/agonists ; Thiazolidinediones/therapeutic use
Chemical Substances	PPAR gamma ; Thiazolidinediones
Language	English
Publishing date	2013-10-23
Publishing country	England
Document type	Journal Article ; Research Support, N.I.H., Extramural ; Comment
ZDB-ID	2107602-9
ISSN	1478-6362 ; 1478-6354
ISSN (online)	1478-6362
ISSN	1478-6354
DOI	10.1186/ar4371
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 5490: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Editorial: Interferon-Targeted Therapy for Systemic Lupus Erythematosus: Are the Trials on Target?

Massarotti, Elena M / Allore, Heather G / Costenbader, Karen

Arthritis & rheumatology (Hoboken, N.J.)

2016 Volume 69, Issue 2, Page(s) 245–248

MeSH term(s)	Antibodies, Monoclonal ; Humans ; Interferon-alpha ; Lupus Erythematosus, Systemic
Chemical Substances	Antibodies, Monoclonal ; Interferon-alpha ; anifrolumab
Language	English
Publishing date	2016-11-16
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	2756371-6
ISSN	2326-5205 ; 2326-5191
ISSN (online)	2326-5205
ISSN	2326-5191
DOI	10.1002/art.39985
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 24: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evolving Use of Molecular Imaging in Research and in Practice.

Tawakol, Ahmed / Unizony, Sebastian / Osborne, Michael T / Massarotti, Elena / Giles, Jon T

Arthritis & rheumatology (Hoboken, N.J.)

2019 Volume 71, Issue 8, Page(s) 1207–1210

MeSH term(s)	Arthritis, Rheumatoid ; Humans ; Molecular Imaging ; Positron-Emission Tomography ; Tomography, X-Ray Computed
Language	English
Publishing date	2019-04-30
Publishing country	United States
Document type	Editorial ; Comment
ZDB-ID	2756371-6
ISSN	2326-5205 ; 2326-5191
ISSN (online)	2326-5205
ISSN	2326-5191
DOI	10.1002/art.40875
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 24: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Interplay Between Systemic Inflammation, Myocardial Injury, and Coronary Microvascular Dysfunction in Rheumatoid Arthritis: Results From the LiiRA Study.

Weber, Brittany / Weisenfeld, Dana / Massarotti, Elena / Seyok, Thany / Cremone, Gabrielle / Lam, Ethan / Golnik, Charlotte / Brownmiller, Seth / Liu, Feng / Huang, Sicong / Todd, Derrick J / Coblyn, Jonathan S / Weinblatt, Michael E / Cai, Tianrun / Dahal, Kumar / Kohler, Minna / Yinh, Janeth / Barrett, Leanne / Solomon, Daniel H /

Plutzky, Jorge / Schelbert, Heinrich R / Campisi, Roxana / Bolster, Marcy B / Di Carli, Marcelo / Liao, Katherine P

Journal of the American Heart Association

2024 Volume 13, Issue 9, Page(s) e030387

Abstract: Background: Coronary microvascular dysfunction as measured by myocardial flow reserve (MFR) is associated with increased cardiovascular risk in rheumatoid arthritis (RA). The objective of this study was to determine the association between reducing ... ...

Abstract	Background: Coronary microvascular dysfunction as measured by myocardial flow reserve (MFR) is associated with increased cardiovascular risk in rheumatoid arthritis (RA). The objective of this study was to determine the association between reducing inflammation with MFR and other measures of cardiovascular risk. Methods and results: Patients with RA with active disease about to initiate a tumor necrosis factor inhibitor were enrolled (NCT02714881). All subjects underwent a cardiac perfusion positron emission tomography scan to quantify MFR at baseline before tumor necrosis factor inhibitor initiation, and after tumor necrosis factor inhibitor initiation at 24 weeks. MFR <2.5 in the absence of obstructive coronary artery disease was defined as coronary microvascular dysfunction. Blood samples at baseline and 24 weeks were measured for inflammatory markers (eg, high-sensitivity C-reactive protein [hsCRP], interleukin-1b, and high-sensitivity cardiac troponin T [hs-cTnT]). The primary outcome was mean MFR before and after tumor necrosis factor inhibitor initiation, with Δhs-cTnT as the secondary outcome. Secondary and exploratory analyses included the correlation between ΔhsCRP and other inflammatory markers with MFR and hs-cTnT. We studied 66 subjects, 82% of which were women, mean RA duration 7.4 years. The median atherosclerotic cardiovascular disease risk was 2.5%; 47% had coronary microvascular dysfunction and 23% had detectable hs-cTnT. We observed no change in mean MFR before (2.65) and after treatment (2.64, Conclusions: In this RA cohort with low prevalence of cardiovascular risk factors, nearly 50% of subjects had coronary microvascular dysfunction at baseline. A reduction in inflammation was not associated with improved MFR. However, a modest reduction in interleukin-1b and no other inflammatory pathways was correlated with a reduction in subclinical myocardial injury. Registration: URL: https://www.clinicaltrials.gov; Unique identifier: NCT02714881.
MeSH term(s)	Humans ; Arthritis, Rheumatoid/physiopathology ; Arthritis, Rheumatoid/complications ; Arthritis, Rheumatoid/blood ; Female ; Male ; Middle Aged ; Inflammation/blood ; Inflammation/physiopathology ; Microcirculation ; Biomarkers/blood ; Coronary Circulation/physiology ; Aged ; Coronary Artery Disease/physiopathology ; Coronary Artery Disease/blood ; Coronary Artery Disease/diagnosis ; Troponin T/blood ; Coronary Vessels/physiopathology ; Coronary Vessels/diagnostic imaging ; C-Reactive Protein/metabolism ; Myocardial Perfusion Imaging/methods ; Interleukin-1beta/blood ; Tumor Necrosis Factor Inhibitors/therapeutic use ; Heart Disease Risk Factors ; Fractional Flow Reserve, Myocardial/physiology ; Positron-Emission Tomography ; Inflammation Mediators/blood ; Antirheumatic Agents/therapeutic use ; Treatment Outcome
Chemical Substances	Biomarkers ; Troponin T ; C-Reactive Protein (9007-41-4) ; Interleukin-1beta ; Tumor Necrosis Factor Inhibitors ; Inflammation Mediators ; Antirheumatic Agents
Language	English
Publishing date	2024-04-30
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Research Support, N.I.H., Extramural
ZDB-ID	2653953-6
ISSN	2047-9980 ; 2047-9980
ISSN (online)	2047-9980
ISSN	2047-9980
DOI	10.1161/JAHA.123.030387
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: The new ACR/EULAR remission criteria: rationale for developing new criteria for remission.

Bykerk, Vivian P / Massarotti, Elena M

Rheumatology (Oxford, England)

2012 Volume 51 Suppl 6, Page(s) vi16–20

Abstract: As more effective treatments for RA have become available, studies have demonstrated that in patients who attained remission, defined as a simplified disease activity index (SDAI) ≤3.3, not only disease activity but radiographic progression was reduced. ... ...

Abstract	As more effective treatments for RA have become available, studies have demonstrated that in patients who attained remission, defined as a simplified disease activity index (SDAI) ≤3.3, not only disease activity but radiographic progression was reduced. The feasibility and the benefit of attaining remission led to the development of the ACR/European League Against Rheumatism (EULAR) 2011 remission criteria. These criteria employ either a Boolean definition, including tender and swollen joint counts ≤1, and CRP ≤1 mg/dl, or an index-based definition, SDAI ≤3.3, in combination with patient-reported outcomes on a scale of 0-10. It is expected that the ACR/EULAR criteria will be used as secondary outcomes in clinical trials. Some questions about the implementation of the new criteria include the availability of CRP values, and the possibility that patient-reported outcomes may skew the outcome if patients cannot distinguish other musculoskeletal conditions from RA. Several issues require further study, including the role of imaging, fatigue and the impact of the involvement of joints other than the 28 counted in the ACR/EULAR criteria.
MeSH term(s)	Antirheumatic Agents/therapeutic use ; Arthritis, Rheumatoid/classification ; Arthritis, Rheumatoid/drug therapy ; Arthritis, Rheumatoid/physiopathology ; C-Reactive Protein/metabolism ; Disease Progression ; Europe ; Humans ; Joints/physiopathology ; Remission Induction ; Societies, Medical ; United States
Chemical Substances	Antirheumatic Agents ; C-Reactive Protein (9007-41-4)
Language	English
Publishing date	2012-12
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	1464822-2
ISSN	1462-0332 ; 1462-0324
ISSN (online)	1462-0332
ISSN	1462-0324
DOI	10.1093/rheumatology/kes281
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 240: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG)
Zs.MO 497: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Inter-library loan at ZB MED

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito